Genetic landscape of patients at diagnosis of chronic myeloid leukemia in the chronic phase: association with targeted therapy efficacy
Background. Despite advances in the treatment of chronic myeloid leukemia (CML), the problem of resistance to tyrosine kinase inhibitors (TKIs) remains unresolved. The role of additional gene mutations (besides BCR::ABL1) in resistance development is widely discussed. These mutations may influence the development of th...